abstract |
The present disclosure relates to peptoids for inhibiting O-GlcNAcylated proteins, and in particular, the c-Rel peptide of NF-kappaB. The compounds can be used in the prevention or treatment of diseases of conditions having elevated levels of O-GlcNAcylation, such as autoimmune diseases, conditions that are related to hyperglycemia, or cancers. |